The 4.6-Point Gap: Why Age Barely Matters for Frozen Donor IVF Success Rates
The Number That Should Reframe Everything You Think About IVF and Age
A 43-year-old woman using frozen donor embryos in 2024 had a 47.4% chance of a live birth per transfer.
A woman under 35 using donor eggs in 2022 achieved 52.0%.
The gap between those two numbers — 4.6 percentage points — is smaller than the margin between getting a good night's sleep and a bad one before your embryo transfer. It is smaller than the variability between two clinics in the same city performing the same procedure on the same age group.
Yet the dominant narrative in fertility medicine is that age is the primary variable. That after 40, your odds collapse. That the window closes. This framing is not wrong exactly — it is just answering the wrong question. Age does matter, but almost entirely through one specific mechanism: egg quality. When you remove that mechanism by using donor eggs or frozen donor embryos, the story changes dramatically.
The 4.6-point spread in the Feralyx dataset is not a rounding error. It is a structural feature of how human reproduction actually works — and most people sitting across from a reproductive endocrinologist have never heard it stated this plainly.
What the Age Cliff Actually Measures
When clinics show you the standard IVF success-rate-by-age chart, the line drops sharply after 37 and falls off a cliff after 40. That chart is real, but it is measuring something specific: cycles using the patient's own eggs.
Own-egg IVF success rates fall with age because egg quality — the chromosomal integrity of the oocyte at the time of retrieval — degrades significantly after the mid-30s. A 42-year-old retrieving her own eggs faces aneuploid rates that can exceed 80% per embryo. Most of those embryos will not implant, and those that do carry elevated miscarriage risk.
But the uterus does not age the same way the ovaries do. Endometrial receptivity — the uterine lining's ability to accept and sustain an embryo — remains relatively stable across a much wider age range. The research on this point is consistent: women in their 40s who carry donor embryos to transfer show endometrial thickness, implantation rates, and early pregnancy continuation rates that are not dramatically different from younger recipients.
This is the mechanism behind that 4.6-point gap. It is not that the data is flattering older patients. It is that the variable most responsible for IVF failure — egg chromosomal quality — has been factored out of the equation when you use donor material.
The Feralyx data reinforces this with a second data point: women aged 35-37 using frozen donor embryos achieved a 48.5% live birth rate in 2023. That is only 3.5 points above the 43-44 cohort in 2024. A two-decade age difference — from early 30s to mid-40s — produces less than a 5-point spread in outcomes when the embryo source is controlled.
The Trend Line Is Moving in One Direction
There is a secondary pattern in the data that deserves attention: frozen donor IVF success rates are improving over time, even within the same age group.
Women aged 35-37 using frozen donor embryos achieved 46.6% live births per transfer in 2019. By 2023, that number had risen to 48.5% — a nearly 2-point gain across four years. This is not a dramatic jump, but the directionality matters. Laboratory protocols, embryo banking techniques, vitrification (the fast-freeze method that replaced slow-freeze and dramatically improved survival rates), and endometrial preparation protocols have all continued to improve.
The under-35 donor cohort followed a similar trajectory: 49.9% in 2018, rising to 52.0% by 2022. That 2.1-point gain over four years represents thousands of additional successful births in aggregate, even as the procedure volume was rising and the patient pool was diversifying.
What this means practically: if you were quoted a success rate by a clinic five or more years ago, that number is probably stale. The benchmark has moved. And it has moved in the direction of patients, not against them.
This is also worth considering when evaluating clinic-reported statistics. A clinic that has not updated its lab protocols or adopted newer vitrification standards since 2018 may be operating with a structural disadvantage that its historical success rates do not reveal. The national trend provides the baseline; the clinic's deviation from that trend — upward or downward — is where the actual signal lives. Explore the full data breakdown at Feralyx to see how clinic-level outcomes compare against these national cohort benchmarks.
The Question Clinics Don't Ask First
Most fertility consultations begin with a workup of the patient's own egg reserve: AMH levels, antral follicle count, day-3 FSH. These are genuinely important numbers. But there is an implicit framing embedded in this sequence — that the goal is always to maximize the patient's own egg contribution, and that donor options are a last resort after own-egg cycles have failed.
The data suggests this sequencing deserves scrutiny, particularly for patients over 38 who are cost-conscious and time-constrained.
A single frozen donor embryo transfer, at $4,000 to $8,000 per cycle depending on clinic and geography, with a 47-49% live birth rate, compares differently to a fresh own-egg IVF retrieval cycle at $15,000 to $25,000 with a success rate that can be substantially lower for patients in their early 40s using their own eggs — sometimes below 10% per transfer for women over 42.
This is not an argument against trying own-egg IVF. For many patients, biological parenthood through their own genetic material is the goal, and that deserves to be honored. But for patients who are ambivalent about the genetic connection, or who have been through multiple failed own-egg cycles, the cost-per-live-birth math changes substantially when you run it against the donor embryo numbers.
A patient who has spent $60,000 across three failed own-egg retrieval cycles may be a single $6,000 frozen donor transfer away from a successful pregnancy — and that option may never have been presented as a parallel path from the beginning of their treatment journey.
How Clinic Selection Changes When You Know This
If frozen donor IVF success rates are relatively stable across a 20-year age range, then the primary variables differentiating clinics are no longer patient age — they are lab quality, protocol rigor, and embryo handling.
This shifts what you should be asking when evaluating clinics:
What is your frozen embryo survival rate post-thaw? Industry standard for vitrification is above 95%. Clinics below 90% have a lab problem that will affect your outcomes regardless of your age or the quality of the donor embryo going in.
What is your endometrial preparation protocol? The difference between a medicated frozen embryo transfer cycle and a natural-cycle transfer is not trivial. Success rates vary by protocol, and the optimal approach depends on individual physiology — clinics that apply the same protocol to everyone are not optimizing.
What is your embryo grading methodology? Not all blastocysts graded "5AA" are equal, and the correlation between visual grade and euploid status is imperfect. Clinics that offer preimplantation genetic testing for aneuploidies (PGT-A) on donor embryos before transfer are removing another major variable from the equation.
These are operational questions, not bedside-manner questions. The 47-52% success rates in the data represent what well-run programs can achieve. A poorly run program operating with the same donor embryo quality may produce rates 10 or 15 points below that. The donor embryo is not a guarantee — it is a ceiling that clinic quality either reaches or fails to reach.
Feralyx's clinic comparison tool lets you layer these protocol variables against reported success rates across age cohorts, so you are not evaluating clinics on headline numbers alone.
What Insurance Mandates Do (and Don't) Cover
One dimension that the success-rate data does not capture is cost access. Frozen donor embryo transfers are covered by fertility insurance mandates in only a subset of states, and coverage terms vary significantly even within mandate states.
States like New York, New Jersey, and Illinois have relatively broad mandates that include donor egg cycles and frozen embryo transfers. States without mandates — the majority of U.S. states — leave patients paying full out-of-pocket costs, which means the $47.4% success rate at $5,000 per transfer compares very differently to the same rate at the same cost when you have zero insurance offset versus full coverage.
This is where geography reintroduces itself into the analysis. The donor embryo data suggests that your uterus location matters less than your insurance mandate location. A 43-year-old in New Jersey with a state mandate covering two frozen donor transfers has a materially different financial risk profile than an identical patient in Texas paying entirely out-of-pocket.
For patients near state lines, this calculus can justify clinic selection across state boundaries. The cost difference between a single covered cycle and a single uncovered cycle can exceed $10,000 — which funds two additional transfer attempts if the first fails.
The success rate data gives you the probability numerator. The insurance coverage data gives you the cost denominator. Neither alone tells you what you need to know.
The Inference the Data Actually Supports
The pattern across the Feralyx dataset — 49.9% (2018, under 35), 52.0% (2022, under 35), 46.6% (2019, 35-37), 48.5% (2023, 35-37), 47.4% (2024, 43-44) — is not random variation. It describes a system where the primary driver of frozen donor IVF success is not the recipient's age but the quality of the embryo, the quality of the lab, and the quality of the preparation protocol.
The age cliff exists, but it lives almost entirely in the ovarian reserve. Remove the ovarian reserve variable through donor embryo use, and what remains is largely uterine biology — which ages more slowly and more uniformly across patients.
This does not mean donor IVF is easy or guaranteed. A 47-48% success rate means a 52-53% failure rate. Multiple transfers may be required. Emotional and physical costs are real and should not be minimized. But the probability structure is fundamentally different from what most 42-year-olds are told when they first walk into a fertility clinic.
The most useful thing this data does is reframe the conversation from "is it too late?" to "what is the right path?" Those are different questions with different answers, and the answer to the second one depends on actual numbers — not on the implicit age pessimism that too often shapes the initial consultation.
If you want to see how these rates break down by clinic type, cycle type, and cohort year — and compare them against what specific programs near you are reporting — the Feralyx data explorer is built specifically for that analysis. The national averages are the starting point. The deviation from them is where the decision lives.
Related Analysis
Other Smart Technology Investments tools that bear on this decision: